Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.58 |
| ▸ | PYGL | P06737 | 8/20 | 0.48 |
| ▸ | PYGM | P11217 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270295 | 1.00 | RIPK1 (0.58) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL13783986 | 0.88 | RIPK1 (0.46) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL12376347 | 0.87 | RIPK1 (0.52) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL1269024 | 0.87 | RIPK1 (0.52) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL14391619 | 0.87 | RIPK1 (0.47) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL1269028 | 0.87 | RIPK1 (0.52) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL15964542 | 0.84 | RIPK1 (0.53) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL12376337 | 0.84 | EPHX2 (0.44) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL12376350 | 0.84 | EPHX2 (0.44) | RIPK1PYGLPYGMGAAEPHX2 | |
| SCHEMBL1269023 | 0.84 | EPHX2 (0.56) | RIPK1PYGLPYGMGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888345-B2 | Benzaepinones as sodium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | TRPV1, TRPA1, KCNN1 | RIPK1 2225/4885PYGL 4545/4885PYGM 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.